AMRI Acquires Majority Interest in Organichem Corporation
Albany Molecular Research, Inc. announced that it has exercised its conversion option with respect to $15 million of Organichem Corporation subordinated debentures. The conversion into additional shares of Organichem common stock took effect on January 1, 2003, and increases AMRI's ownership in Organichem from 39.2% to 75%.
"The debenture conversion is a step towards AMRI's ultimate purchase of Organichem, which we expect to occur within the next few months," said AMRI Chairman and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "Ownership of Organichem will provide AMRI customers with a one-stop, continuous range of resources from bench-scale synthesis to commercial cGMP manufacturing."
Organichem Corporation was founded in 1999 through a management led buyout of the Nycomed Amersham plc chemical manufacturing facility in Rensselaer, New York. AMRI was a founding investor in the formation of Organichem which was announced on December 21, 1999. AMRI's investment in Organichem included a $15 million equity investment for a 37.5% ownership and $15 million in debentures, which could be converted into additional equity in Organichem after three years.
The December 1999 investment agreement with Organichem also gave AMRI the option to purchase the remaining Organichem shares subsequent to the completion of Organichem's 2002 audited financial statements. AMRI has previously communicated its intention to exercise the purchase option. The purchase price is to be determined based on Organichem's financial performance in the year 2002. At this time, it is estimated that the purchase price will be approximately $30 million.
AMRI will begin consolidating Organichem's operating results effective January 1, 2003. In its previous status as a minority shareholder, AMRI only included its proportionate share of Organichem's net income in its income statement as equity in income of unconsolidated affiliates.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Possible trigger of Crohn’s disease discovered
Dysfunctional mitochondria disrupt the gut microbiome
Cost-effective modular system for optical imaging from the 3D printer
Like building with Lego bricks
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
